

Martine Bagot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2586230/publications.pdf>

Version: 2024-02-01

102
papers

2,671
citations

186265

28
h-index

206112

48
g-index

103
all docs

103
docs citations

103
times ranked

3470
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chloroquine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides. <i>Dermatology</i> , 2022, 238, 347-357. | 2.1 | 9 |
| 2 | Acropulpsitis in systemic lupus erythematosus is associated with high type 1 interferon signature. <i>Experimental Dermatology</i> , 2022, 31, 819-820. | 2.9 | 0 |
| 3 | Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. <i>Cancer</i> , 2022, 128, 1004-1014. | 4.1 | 12 |
| 4 | Clinical, pathological, and molecular features of myelodysplasia cutis. <i>Blood</i> , 2022, 139, 1251-1253. | 1.4 | 15 |
| 5 | Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome*. <i>British Journal of Dermatology</i> , 2022, 186, 1010-1025. | 1.5 | 10 |
| 6 | The importance of dosage for naltrexone treatment in Hailey-Hailey disease. <i>JAAD Case Reports</i> , 2022, 23, 155-157. | 0.8 | 0 |
| 7 | Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome. <i>Blood</i> , 2022, 139, 2712-2716. | 1.4 | 14 |
| 8 | Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides. <i>British Journal of Dermatology</i> , 2022, 187, 129-131. | 1.5 | 4 |
| 9 | Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach. <i>British Journal of Dermatology</i> , 2022, 187, 21-28. | 1.5 | 9 |
| 10 | Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries. <i>Cancers</i> , 2022, 14, 145. | 3.7 | 7 |
| 11 | Clinical characteristics of Mycosis fungoides palmaris et plantaris: two cases and a systematic literature review. <i>European Journal of Dermatology</i> , 2022, 32, 421-423. | 0.6 | 0 |
| 12 | TH cell diversity and response to dupilumab in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 756-759. | 2.9 | 20 |
| 13 | Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. <i>Journal of Investigative Dermatology</i> , 2021, 141, 193-197.e2. | 0.7 | 4 |
| 14 | Mogamulizumab-induced vitiligo in patients with Sezary syndrome: three cases. <i>European Journal of Dermatology</i> , 2021, 31, 213-216. | 0.6 | 10 |
| 15 | Suppurative keloids: a complication of severe keloid disease. <i>International Journal of Dermatology</i> , 2021, 60, 1392-1396. | 1.0 | 6 |
| 16 | Chloroquine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. <i>Dermatology and Therapy</i> , 2021, 11, 1085-1106. | 3.0 | 16 |
| 17 | Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS. <i>Haematologica</i> , 2021, 106, 3245-3248. | 3.5 | 18 |
| 18 | PAK1-Dependent Antitumor Effect of AAC-11-Derived Peptides on Sezary Syndrome Malignant CD4+ T Lymphocytes. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2261-2271.e5. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | <i>UBA1</i> Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349. | 4.1 | 71 |
| 20 | Large cell transformation is an independent prognostic factor in SÅ©zary syndrome: a retrospective analysis of 117 cases. <i>European Journal of Cancer</i> , 2021, 156, S25. | 2.8 | 0 |
| 21 | Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing. <i>European Journal of Cancer</i> , 2021, 156, S3-S4. | 2.8 | 3 |
| 22 | ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. <i>European Journal of Cancer</i> , 2021, 156, S23-S24. | 2.8 | 1 |
| 23 | Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and SÅ©zary syndrome with the KIR3DL2 marker. <i>European Journal of Cancer</i> , 2021, 156, S6-S7. | 2.8 | 0 |
| 24 | Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series. <i>European Journal of Cancer</i> , 2021, 156, S49. | 2.8 | 1 |
| 25 | Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIbâ€“IVB mycosis fungoides/SÅ©zary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). <i>European Journal of Cancer</i> , 2021, 156, S22-S23. | 2.8 | 3 |
| 26 | Is mogamulizumab-induced alopecia areata associated with favorable outcomes in SÅ©zary syndrome?. <i>European Journal of Cancer</i> , 2021, 156, S50-S51. | 2.8 | 4 |
| 27 | ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. <i>Blood</i> , 2021, 138, 790-790. | 1.4 | 4 |
| 28 | Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. <i>Cancers</i> , 2020, 12, 2921. | 3.7 | 57 |
| 29 | Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. <i>Cancers</i> , 2020, 12, 2856. | 3.7 | 10 |
| 30 | In vivo multiphoton imaging for nonâ€“invasive time course assessment of retinoids effects on human skin. <i>Skin Research and Technology</i> , 2020, 26, 794-803. | 1.6 | 12 |
| 31 | ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214. | 5.2 | 18 |
| 32 | Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 667-670. | 1.2 | 144 |
| 33 | Zoon's plasma cell balanitis associated with male genital lichen sclerosus. <i>JAAD Case Reports</i> , 2020, 6, 670-672. | 0.8 | 2 |
| 34 | Granular parakeratosis involving the glans of the penis and foreskin. <i>Journal of Dermatology</i> , 2020, 47, e295-e296. | 1.2 | 0 |
| 35 | Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. <i>Cancers</i> , 2020, 12, 1497. | 3.7 | 15 |
| 36 | Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweetâ€“s Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5. | 0.7 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Uncommon presentation of pigmented paraungual basal cell carcinoma on the first toe treated with total excision. <i>Dermatologic Therapy</i> , 2020, 33, e13289. | 1.7 | 1 |
| 38 | Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2777-2779.e1. | 3.8 | 20 |
| 39 | MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN- β Transcript. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1276-1279.e7. | 0.7 | 30 |
| 40 | HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061. | 1.4 | 29 |
| 41 | Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1166-1170. | 1.2 | 6 |
| 42 | Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of S α Czary Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2019, 139, 725-728. | 0.7 | 6 |
| 43 | Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin. <i>Dermatology and Therapy</i> , 2019, 9, 383-388. | 3.0 | 14 |
| 44 | Increased CD8+CD28- circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 755-758. | 1.2 | 1 |
| 45 | Congenital yellow nail syndrome presenting with eyelid lymphedema and fetal hydrops. <i>JAAD Case Reports</i> , 2019, 5, 1010-1012. | 0.8 | 3 |
| 46 | Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37. | 0.7 | 55 |
| 47 | Asymetric red-blue hypertrophic hand and tenosynovitis due to acrodermatitis chronica atrophicans. <i>Rheumatology</i> , 2019, 58, 655-655. | 1.9 | 0 |
| 48 | Blood classification and blood response criteria in mycosis fungoides and S α Czary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. <i>European Journal of Cancer</i> , 2018, 93, 47-56. | 2.8 | 105 |
| 49 | Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 945-947. | 1.2 | 10 |
| 50 | A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg λ Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989. | 0.7 | 27 |
| 51 | Cytokine levels in persistent skin lesions of adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 947-949. | 1.2 | 8 |
| 52 | Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 969-971. | 1.2 | 18 |
| 53 | Palliative Radiotherapy for Disfiguring Mycosis Fungoides Lesion: A Key Treatment to Reduce Psychological and Social Impact. <i>Case Reports in Dermatological Medicine</i> , 2018, 2018, 1-4. | 0.3 | 0 |
| 54 | Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 67, 1197-1208. | 4.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs, 2018, 27, 691-697. | 4.1 | 12 |
| 56 | Increased Expression of PLS3 Correlates with Better Outcome in SÅ©zary Syndrome. Journal of Investigative Dermatology, 2017, 137, 754-757. | 0.7 | 7 |
| 57 | Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with SÅ©zary Syndrome. Clinical Cancer Research, 2017, 23, 3619-3627. | 7.0 | 41 |
| 58 | Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Seminars in Arthritis and Rheumatism, 2017, 47, 281-287. | 3.4 | 42 |
| 59 | Focal Pegylated Liposomal Doxorubicinâ€“Induced Urticarialike Reaction at Cutaneous Transformed SÅ©zary Lesions. JAMA Dermatology, 2017, 153, 475. | 4.1 | 1 |
| 60 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. European Journal of Dermatology, 2017, 27, 286-294. | 0.6 | 16 |
| 61 | Circulating and skin-derived SÅ©zary cells: clonal but with phenotypic plasticity. Blood, 2017, 130, 1468-1471. | 1.4 | 44 |
| 62 | Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. European Journal of Dermatology, 2017, 27, 271-274. | 0.6 | 11 |
| 63 | Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatology, 2017, 153, 184. | 4.1 | 17 |
| 64 | 18F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin. European Journal of Dermatology, 2017, 27, 496-504. | 0.6 | 5 |
| 65 | New targeted treatments for cutaneous T-cell Lymphomas. Indian Journal of Dermatology, 2017, 62, 142. | 0.3 | 13 |
| 66 | Infliximab in recalcitrant granuloma annulare. International Journal of Dermatology, 2016, 55, 220-222. | 1.0 | 5 |
| 67 | Reply to: â€œThe relationship between lymphocytic thrombophilic arteritis and cutaneous polyarteritis nodosaâ€. Journal of the American Academy of Dermatology, 2016, 75, e245-e246. | 1.2 | 0 |
| 68 | Evaluation of Immunophenotypic and Molecular Biomarkers for SÅ©zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. Journal of Investigative Dermatology, 2016, 136, 1364-1372. | 0.7 | 78 |
| 69 | Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2016, 136, 1302-1305. | 0.7 | 1 |
| 70 | Epigenomic Analysis of SÅ©zary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers. Journal of Investigative Dermatology, 2016, 136, 1876-1884. | 0.7 | 46 |
| 71 | Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. Chest, 2016, 149, e133-e136. | 0.8 | 142 |
| 72 | Expression of SÅ©zary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. Journal of Investigative Dermatology, 2016, 136, 317-320. | 0.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>Oncolmmunology</i> , 2016, 5, 1136045. | 4.6 | 22 |
| 74 | First case of chancroid in 14 years at the largest STI clinic in Paris, France. <i>International Journal of STD and AIDS</i> , 2016, 27, 805-807. | 1.1 | 7 |
| 75 | Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. <i>Oncologist</i> , 2016, 21, 76-83. | 3.7 | 42 |
| 76 | Certolizumab pegol â€“ A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohnâ€™s disease. <i>Journal of Dermatological Treatment</i> , 2016, 27, 67-69. | 2.2 | 29 |
| 77 | Necrotizing cellulitis with multiple abscesses on the leg caused by <i>Serratia marcescens</i> . <i>Cutis</i> , 2016, 97, E8-E12. | 0.3 | 2 |
| 78 | Early-Onset Atopic Dermatitis in Children: Which Are the Phenotypes at Risk of Asthma? Results from the ORCA Cohort. <i>PLoS ONE</i> , 2015, 10, e0131369. | 2.5 | 49 |
| 79 | The High Expression of the microRNA 17â€™92 Cluster and its Paralogs, and the Downregulation of the Target Gene PTEN, Is Associated with Primary Cutaneous B-Cell Lymphoma Progression. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1659-1667. | 0.7 | 34 |
| 80 | Posaconazole Treatment of Extensive Skin and Nail Dermatophytosis Due to Autosomal Recessive Deficiency of CARD9. <i>JAMA Dermatology</i> , 2015, 151, 192. | 4.1 | 71 |
| 81 | SÃ©zary syndrome without erythroderma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1003-1009.e1. | 1.2 | 19 |
| 82 | Therapeutic management of DRESS: A retrospective study of 38 cases. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 246-252. | 1.2 | 110 |
| 83 | KIR3DL2/CpG ODN Interaction Mediates SÃ©zary Syndrome Malignant T Cell Apoptosis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 229-237. | 0.7 | 14 |
| 84 | Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. <i>JAMA Dermatology</i> , 2015, 151, 1030. | 4.1 | 8 |
| 85 | Deficient regulatory B cells in human chronic graft-versus-host disease. <i>Oncolmmunology</i> , 2015, 4, e1016707. | 4.6 | 11 |
| 86 | Authors' Reply. <i>American Journal of Pathology</i> , 2015, 185, 1168. | 3.8 | 1 |
| 87 | CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 1830-1839. | 1.4 | 144 |
| 88 | Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): Blinded histologic assessment of 35 cPAN cases. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 1013-1020. | 1.2 | 40 |
| 89 | CD158k Is a Reliable Marker for Diagnosis of SÃ©zary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 247-257. | 0.7 | 56 |
| 90 | IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma. <i>Cancer Research</i> , 2014, 74, 6060-6070. | 0.9 | 65 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | HACE1, a Potential Tumor Suppressor Gene on 6q21, Is Not Involved in Extranodal Natural Killer/T-Cell Lymphoma Pathophysiology. <i>American Journal of Pathology</i> , 2014, 184, 2899-2907. | 3.8 | 13 |
| 92 | Emergency Department Diagnosis and Management of Skin Diseases With Real-Time Teledermatologic Expertise. <i>JAMA Dermatology</i> , 2014, 150, 743. | 4.1 | 41 |
| 93 | KIR3DL2 is a coinhibitory receptor on S zary syndrome malignant T cells that promotes resistance to activation-induced cell death. <i>Blood</i> , 2014, 124, 3330-3332. | 1.4 | 22 |
| 94 | In vivo multiphoton imaging of human skin: assessment of topical corticosteroid-induced epidermis atrophy and depigmentation. <i>Journal of Biomedical Optics</i> , 2012, 17, 026009. | 2.6 | 35 |
| 95 | EORTC 21012: Phase II Multicentre Study of Caelyx,   Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.. <i>Blood</i> , 2010, 116, 2823-2823. | 1.4 | 1 |
| 96 | The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. <i>Blood</i> , 2010, 116, 4896-4896. | 1.4 | 0 |
| 97 | CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of S zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2008, 128, 465-472. | 0.7 | 51 |
| 98 | Significance of circulating T-cell clones in Sezary syndrome. <i>Blood</i> , 2006, 107, 4030-4038. | 1.4 | 69 |
| 99 | CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2004, 122, 820-823. | 0.7 | 135 |
| 100 | Killer cell immunoglobulin-like receptor expression delineates in situ S zary syndrome lymphocytes. <i>Journal of Pathology</i> , 2003, 199, 77-83. | 4.5 | 47 |
| 101 | CD4+ cutaneous T-cell lymphoma cells express the p140   killer cell immunoglobulin-like receptor. <i>Blood</i> , 2001, 97, 1388-1391. | 1.4 | 119 |
| 102 | Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. <i>European Journal of Immunology</i> , 2000, 30, 3132-3139. | 2.9 | 35 |